Eli Lilly raises forecasts on surging international demand for weight-loss drugs

Eli Lilly's stock surged after announcing record-breaking earnings, driven by its weight-loss drugs Zepbound and Mounjaro. Despite concerns, Zepbound sales in the US remained strong, and Mounjaro sales internationally exceeded expectations. Lilly's market value now rivals Novo Nordisk's, and analysts predict the weight-loss drug market could reach $150 billion by 2030. Lilly raised its profit and revenue forecasts for the year, with earnings per share projected at $23.70, up from $22.50 earlier.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.